Guardant Health (GH) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Guardant Health published the results on November 5, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Guardant Health reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Guardant Health reports in thousands of dollars; figures here are in millions. Its non-GAAP net loss excludes stock-based compensation and related payroll tax ($66.3 million in Q3 2026), amortization of intangibles and $19.0 million of other items, which include contingent consideration and non-recurring legal expenses.

Source: Guardant Health Q3 2026 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Guardant Health splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Guardant Health's Oncology revenue was $231 million in Q3 2026, up 25% from $184 million in Q3 2025, 64% of total revenue.
• Guardant Health's Biopharma and data revenue was $59.0 million in Q3 2026, up 8% from $54.7 million in Q3 2025, 16% of total revenue.
• Guardant Health's Screening revenue was $67.6 million in Q3 2026, up 180% from $24.1 million in Q3 2025, 19% of total revenue.
• Guardant Health's Licensing and other revenue was $3.1 million in Q3 2026, up 60% from $2.0 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Guardant Health said:

“Guardant Health now expects full year 2026 revenue to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025.”

“Screening revenue is now expected to be in the range of $233 to $238 million, driven by Shield volume of 285,000 to 290,000 tests.”

“Guardant Health now expects full year 2026 non-GAAP gross margin to be 65%, compared to prior guidance of 64% to 65%.”

“Guardant Health now expects full-year free cash flow burn of $205 million to $220 million, compared to the previous outlook of $195 million to $205 million.”

Source: Guardant Health Q3 2026 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the GH forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and net loss per share (basic and diluted), each as first reported in that quarter's release.

We do not hold a confirmed date for Guardant Health's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 5, 2026

Guardant Health had revenue of $361.0 million in Q3 2026, up 36% from $265.2 million. Oncology testing is the largest part at $231.3 million, up 25%, followed by Screening at $67.6 million, Biopharma & Data at $59.0 million and licensing and other at $3.1 million. (Guardant Health Q3 2026 release, Nov 5, 2026)

Guardant ran about 117,000 oncology tests in the quarter, up 58% from about 74,000, while oncology revenue rose 25%. Its oncology tests include Guardant360 CDx, which in the quarter won FDA approval as a companion diagnostic for AstraZeneca's camizestrant, the first FDA-approved liquid biopsy companion diagnostic for longitudinal testing in breast cancer. (Guardant Health Form 10-Q, Q3 2026, Nov 5, 2026; Guardant Health Q3 2026 release, Nov 5, 2026)

Screening is the Shield blood test for colorectal cancer, the first blood test approved by the FDA for primary colorectal cancer screening. Screening revenue grew 180% to $67.6 million as Shield volume rose to about 83,000 tests from about 24,000. Guardant said commercial coverage for Shield now reaches more than 80% of eligible lives, with UnitedHealth Group, Carelon Healthcare Services and EviCore among the additions. (Guardant Health Q3 2026 release, Nov 5, 2026; Guardant Health Form 10-Q, Q3 2026, Nov 5, 2026)

Biopharma & Data revenue, from tests and data services sold to drug developers, rose 8% to $59.0 million, driven mainly by volume of the GuardantINFINITY test. Revenue attributable to Medicare was more than 10% of total revenue in each of 2025, 2024 and 2023. (Guardant Health Form 10-Q, Q3 2026, Nov 5, 2026; Guardant Health Form 10-K, 2025, Feb 19, 2026)

Guardant Health lost $0.93 per share under GAAP in Q3 2026, against $0.74 a year earlier, and its non-GAAP net loss per share narrowed to $0.29 from $0.39. Net loss was $124.4 million. The non-GAAP figure excludes $66.3 million of stock-based compensation and related payroll tax, $279 thousand of intangible amortization and $19.0 million of other items, which Guardant defines to include contingent consideration and non-recurring legal expenses. (Guardant Health Q3 2026 release, Nov 5, 2026)

Operating expenses were $368.9 million, up from $270.6 million, which Guardant tied to commercial infrastructure and marketing for Screening and Oncology and higher stock-based compensation. General and administrative expense rose 71% to $90.9 million, mainly from a $22.6 million net increase in legal expenses and $11.4 million more stock-based compensation. (Guardant Health Q3 2026 release, Nov 5, 2026; Guardant Health Form 10-Q, Q3 2026, Nov 5, 2026)

Gross margin was 65% on a GAAP basis and 67% non-GAAP. Weighted average shares rose to 134,422 thousand from 124,807 thousand. Adjusted EBITDA was a loss of $37.3 million, against a $45.5 million loss a year earlier, and free cash flow was $(37.2) million. (Guardant Health Q3 2026 release, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Guardant Health raised its full year 2026 revenue guidance to $1.36 to $1.37 billion, or 38% to 40% growth, from $1.34 to $1.36 billion. It expects Oncology revenue to grow about 30% on volume growth of over 50%, Biopharma & Data growth in the low double digits, and Screening revenue of $233 to $238 million on 285,000 to 290,000 Shield tests. (Guardant Health Q3 2026 release, Nov 5, 2026)

On costs, Guardant now expects a non-GAAP gross margin of 65% and non-GAAP operating expenses of $1.105 to $1.125 billion, up from $1.080 to $1.100 billion, and it widened its expected full-year free cash flow burn to $205 million to $220 million from $195 million to $205 million. (Guardant Health Q3 2026 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Guardant Health, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Guardant Health's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning GH is on is GH a buy or a sell?, what analysts expect next is on the GH forecast, and what the company does is on the Guardant Health (GH) stock page.

Every number on this page can be traced to a document Guardant Health published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.